IDEXX Laboratories, Inc. stock research
FY2025 Q2
IDEXX Laboratories (IDXX) Gross Margin — Quarter Ended Jun 30, 2025
Revenue, gross profit, and cost of revenue all increased compared with the prior quarter and the year-ago quarter. Gross margin improved over both periods, as gross profit rose more than revenue.
Gross margin takeaway
Quarter ended Jun 30, 2025 · FY2025 Q2
Revenue, gross profit, and cost of revenue all increased compared with the prior quarter and the year-ago quarter. Gross margin improved over both periods, as gross profit rose more than revenue.
- The improvement in gross margin was supported by a larger increase in gross profit relative to the increase in revenue.
- Gross margin was higher than the immediately preceding quarter and higher than the same quarter one year earlier.
Gross margin snapshot
The selected quarter's reported revenue, gross profit, direct costs, and margin comparisons.
Gross margin
62.6%
Gross profit
$694.7M
Revenue
$1.1B
Cost of revenue
$414.7M
Quarter-over-quarter change
+0.2 pts
Year-over-year change
+0.9 pts
Quarterly gross margin trend
A four-quarter view of the revenue and direct-cost bridge behind gross margin.
| Period | Revenue | Gross profit | Cost of revenue | Gross margin |
|---|---|---|---|---|
| Sep 30, 2024 | $975.5M | $596.0M | $379.5M | 61.1% |
| Dec 31, 2024 | $954.3M | $570.7M | $383.6M | 59.8% |
| Mar 31, 2025 | $998.4M | $623.4M | $375.0M | 62.4% |
| Jun 30, 2025 | $1.1B | $694.7M | $414.7M | 62.6% |
Quarterly comparisons
Compare the selected margin with the preceding quarter and the same fiscal quarter one year earlier.
Previous-quarter change
Mar 31, 2025
+0.2 pts
Year-over-year change
Jun 30, 2024
+0.9 pts
What the margin says
Filing-constrained interpretation of margin direction, comparisons, and what to monitor next.
The improvement in gross margin was supported by a larger increase in gross profit relative to the increase in revenue.
Gross margin was higher than the immediately preceding quarter and higher than the same quarter one year earlier.
Per the filing, trends in companion animal healthcare and distributor purchasing and inventories are noted as relevant to the company's outlook.